A Phase 2 interventional study of LY3541860 and Placebo in Multiple Sclerosis, sponsored by Eli Lilly and Company. Terminated at 20 sites in 7 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
LY3541860 Phase 2a Dose Level 1 · LY3541860 Phase 2a Dose Level 2 · Placebo Phase 2a · LY3541860 Phase 2b Dose Level 3 · LY3541860 Phase 2b Dose Level 4 · Placebo Phase 2b
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 150 studies in Multiple Sclerosis with a site in Poland — 9 open to participants now, 30 under way, 18 of them phase 3. Multiple Sclerosis · Poland.
Among the 150 studies in Multiple Sclerosis with a site in Poland, this one is the 121st largest by enrollment of the 134 interventional ones that give a count, is one of 4 that started in 2024, is one of 35 in phase 2, and was the 138th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →9 of the 150 studies in Multiple Sclerosis with a site in Poland are open now. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in Poland, United States, Slovakia
Ages 10–17
TG Therapeutics, Inc. · Sites in Poland, Bosnia and Herzegovina, Georgia and 3 more countries
Ages 18–65
Novartis Pharmaceuticals · Sites in Poland, United States, Argentina and 33 more countries
Ages 18–65
Hoffmann-La Roche · Sites in Poland, Argentina, Brazil and 4 more countries
Ages 10–17
Celgene · Sites in Poland, United States, Australia and 4 more countries
Ages 18–70
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
150 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 41 · Phase 3 81 · Phase 4 10
First in 2002; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 435 across the 134 interventional studies, 387 across the 16 observational. Of the 118 that completed or were terminated, 89 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
144 of 150 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 4 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Multiple Sclerosis with a site in Poland that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05134441Phase 3Immunic AGStudy to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | 2026-11 |
| NCT05877963Phase 3TG Therapeutics, Inc.Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | 2027-01-21 |
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT05961644Phase 3Institute of Psychiatry and Neurology, WarsawCladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). | 2027-06-30 |
| NCT06668649Jakub AntczakPolish Version Fatigue Severity Scale | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 150 studies in Multiple Sclerosis with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have 1 of these:
Exclusion Criteria:
Have had a diagnosis of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a high dose of LY3541860 administered intravenously (IV) over a period of 36 weeks.
Drug: LY3541860
Participants received LY3541860-matching placebo for 12 weeks, followed by a low dose of LY3541860 administered intravenously (IV) over a period of 24 weeks.
Drug: LY3541860 · Drug: Placebo
Administered IV
Administered IV
Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions
The cumulative number of new T1 gadolinium-enhancing (GdE) lesions observed on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) estimator with a negative binomial regression outcome model adjusted for geographic region (North America versus Rest of World) and presence of T1 GdE lesions at baseline (0 or ≥1).
Time frame: 12 Weeks
Cumulative Number of Total Number of T1 GdE Lesions
The cumulative number of total number of T1 gadolinium-enhancing (GdE) lesions observed on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) estimator with a negative binomial regression outcome model adjusted for geographic region (North America versus Rest of World) and presence of T1 GdE lesions at baseline (0 or ≥1).
Time frame: 12 Weeks
Cumulative Number of New and/or Enlarging T2 Lesions
The cumulative number of new and/or enlarging T2 lesions identified on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) approach with a negative binomial regression outcome model adjusted for geographic region (North America vs Rest of World) and presence of T1 gadolinium-enhancing lesions at baseline (0 vs ≥1).
Time frame: 12 Weeks
Pharmacokinetics (PK): Observed Plasma Trough Concentrations of LY3541860 at Week 12
Observed Plasma trough concentrations (Ctrough) of LY3541860.
Time frame: Predose at Week 12
| Milestone | LY3541860 High Dose | Placebo / LY3541860 Low Dose |
|---|---|---|
| Started | 34 | 31 |
| All participants who received at least 1 dose of the study intervention | 34 | 31 |
| Completed | 13 | 12 |
| Not completed | 21 | 19 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 6 | 5 |
| Withdrew: Study terminated by the sponsor | 15 | 11 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
The cumulative number of new T1 gadolinium-enhancing (GdE) lesions observed on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) estimator with a negative binomial regression outcome model adjusted for geographic region (North America versus Rest of World) and presence of T1 GdE lesions at baseline (0 or ≥1).
| Cumulative number of lesions | LY3541860 High Dose | Placebo / LY3541860 Low Dose |
|---|---|---|
| Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions | 1.11 ± 0.316 | 1.56 ± 0.791 |
The cumulative number of total number of T1 gadolinium-enhancing (GdE) lesions observed on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) estimator with a negative binomial regression outcome model adjusted for geographic region (North America versus Rest of World) and presence of T1 GdE lesions at baseline (0 or ≥1).
| Cumulative number of lesions | LY3541860 High Dose | Placebo / LY3541860 Low Dose |
|---|---|---|
| Cumulative Number of Total Number of T1 GdE Lesions | 1.38 ± 0.401 | 1.82 ± 0.866 |
The cumulative number of new and/or enlarging T2 lesions identified on MRI scans during the treatment period. Treatment group means were estimated using an augmented inverse propensity weighted (AIPW) approach with a negative binomial regression outcome model adjusted for geographic region (North America vs Rest of World) and presence of T1 gadolinium-enhancing lesions at baseline (0 vs ≥1).
| Cumulative number of lesions | LY3541860 High Dose | Placebo / LY3541860 Low Dose |
|---|---|---|
| Cumulative Number of New and/or Enlarging T2 Lesions | 2.66 ± 0.870 | 3.92 ± 1.954 |
Observed Plasma trough concentrations (Ctrough) of LY3541860.
| nanogram per milliliter (ng/mL) | LY3541860 High Dose |
|---|---|
| Pharmacokinetics (PK): Observed Plasma Trough Concentrations of LY3541860 at Week 12 | 93300 ± 36.4 |
Collected over Baseline to End of Safety Follow-up (up to 60 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY3541860 High Dose | 0/34 (0%) | 3/34 (8.8%) | 27/34 (79.4%) |
| Placebo / LY3541860 Low Dose | 0/31 (0%) | 2/31 (6.5%) | 21/31 (67.7%) |
| Event | LY3541860 High Dose | Placebo / LY3541860 Low Dose |
|---|---|---|
| Abnormal uterine bleedingReproductive system and breast disorders | 0/23 | 1/20 |
| AppendicitisInfections and infestations | 0/34 | 1/31 |
| Cardiac failureCardiac disorders | 1/34 | 0/31 |
| Myocardial infarctionCardiac disorders | 1/34 | 0/31 |
| PneumoniaInfections and infestations | 1/34 | 0/31 |
| Rectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/34 | 0/31 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/34 | 0/31 |
| Event | LY3541860 High Dose | Placebo / LY3541860 Low Dose |
|---|---|---|
| NasopharyngitisInfections and infestations | 7/34 | 4/31 |
| Upper respiratory tract infectionInfections and infestations | 4/34 | 4/31 |
| Urinary tract infectionInfections and infestations | 3/34 | 4/31 |
| FatigueGeneral disorders | 4/34 | 0/31 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/34 | 3/31 |
| HeadacheNervous system disorders | 3/34 | 3/31 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/34 | 1/31 |
| ParaesthesiaNervous system disorders | 3/34 | 1/31 |
| DiarrhoeaGastrointestinal disorders | 2/34 | 2/31 |
| AstheniaGeneral disorders | 0/34 | 2/31 |
All participants who received at least 1 dose of the study intervention.
| Age, Continuous(years) | LY3541860 High Dose | Placebo / LY3541860 Low Dose | Total |
|---|---|---|---|
| Mean | 39.2 ± 11.43 | 36.1 ± 10.50 | 37.7 ± 11.02 |
| Sex: Female, Male(Participants) | LY3541860 High Dose | Placebo / LY3541860 Low Dose | Total |
|---|---|---|---|
| Female | 23 | 20 | 43 |
| Male | 11 | 11 | 22 |
| Ethnicity (NIH/OMB)(Participants) | LY3541860 High Dose | Placebo / LY3541860 Low Dose | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 33 | 30 | 63 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | LY3541860 High Dose | Placebo / LY3541860 Low Dose | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 34 | 30 | 64 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | LY3541860 High Dose | Placebo / LY3541860 Low Dose | Total |
|---|---|---|---|
| France | 3 | 0 | 3 |
| Germany | 2 | 0 | 2 |
| Italy | 0 | 3 | 3 |
| Latvia | 2 | 2 | 4 |
| Lithuania | 1 | 3 | 4 |
| Poland | 20 | 17 | 37 |
| Slovakia | 1 | 1 | 2 |
| United States | 5 | 5 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2024 to primary completion in Oct 2025, 18 months.
Results were first posted in Nov 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
LY3541860 Phase 2a Dose Level 1 · LY3541860 Phase 2a Dose Level 2 · Placebo Phase 2a · LY3541860 Phase 2b Dose Level 3 · LY3541860 Phase 2b Dose Level 4 · Placebo Phase 2b
LY3541860 Phase 2a Dose Level 1 · LY3541860 Phase 2a Dose Level 2 · Placebo Phase 2a · LY3541860 Phase 2b Dose Level 3 · LY3541860 Phase 2b Dose Level 4 · Placebo Phase 2b
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sevoloprubart